Cardiovascular Inflammation is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cardiovascular Inflammation have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cardiovascular Inflammation compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cardiovascular Inflammation overview
Cardiovascular inflammation refers to inflammation that occurs in the blood vessels, heart tissues, or both, contributing to various cardiovascular diseases. Inflammation is the body’s natural response to injury or infection, but when it becomes chronic or excessive, it can play a role in the development and progression of cardiovascular conditions. The factors can contribute to cardiovascular inflammation, including smoking, obesity, a diet high in saturated fats and sugars, sedentary lifestyle, and chronic diseases like diabetes
See Also:
For a complete picture of PTSR and LoA scores for drugs in Cardiovascular Inflammation, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
